ZALEVSKY JONATHAN (Chief R&D Officer) sold 5.7% of their position (1.16K shares) of NEKTAR THERAPEUTICS on the open market
Open‑market sale worth $62.8K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 11/25/2025ACC: 0001193125-25-297855
Officer· Chief R&D Officer
Since Oct 2019
+6.28K
Net shares
Net buyer
$62.8K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
7.43K acquired · 1.16K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+2.67K
Price / share
—
Trade value
—
% of position
15.3%
11/21/2025
17.46K→20.13K
Common Stock
Direct
Shares
−1.16K
Price / share
$54.28
Trade value
$62.80K
% of position
5.7%
11/25/2025
20.13K→18.97K
Total
Net shares
+1.51K
Net value
-$62.80K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 11/21/2025 | A · Award | +2.67K | — | — | 15.3% | 17.46K | 20.13K |
| Common Stock Direct | 11/25/2025 | S · Sale | −1.16K | $54.28 | $62.80K | 5.7% | 20.13K | 18.97K |
| Total | +1.51K | -$62.80K | ||||||
Derivative Transactions1
Stock Option
Direct
Converts to
Common Stock
4.77K shares
Shares
+4.77K
Strike price
281.25
Held after
4.77K
Exercisable
—
11/21/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option Direct | Common Stock4.77K shares | 11/21/2025 | A · Award | +4.77K | 281.25 | — | 4.77K |